Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Study Evaluating the Safety of Adding Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin-doxorubicin to the Systemic Chemotherapy, and the Recommended Phase II Dose, in Women With Insufficient Response to Carboplatin-paclitaxel for Advanced Epithelial Cancer of the Ovary, Fallopian Tubes or Peritoneum

NCT04811703 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT04811703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04811703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Study Evaluating the Safety of Adding Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin-doxorubicin to the Systemic Chemotherapy, and the Recommended Phase II Dose, in Women With Insufficient Response to Carboplatin-paclitaxel for Advanced Epithelial Cancer of the Ovary, Fallopian Tubes or Peritoneum
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 1
Overall status
Recruiting
Start date
July 30, 2021
Completion date
January 31, 2029
Enrollment
15 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm in the peritoneum, metastatic ovarian carcinoma, peritoneal carcinomatosis, stage iib fallopian tube cancer, stage iib ovarian cancer, stage iii fallopian tube cancer, stage iii ovarian cancer, stage iva fallopian tube cancer, stage iva ovarian cancer